Novartis to Acquire Avidity Biosciences for $12B Ahead of Cardiology Spin-Off

Introduction

Avidity Biosciences Inc (Nasdaq: RNA) is a biopharmaceutical company headquartered in San Diego, California, focused on a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™). The company aims to improve patient outcomes by combining the targeting specificity of monoclonal antibodies with the precision of oligonucleotides. Its pipeline addresses genetic neuromuscular diseases and is expanding into cardiology and immunology through internal programs and external partnerships.

Corporate Structure

Avidity employs between 51 and 200 staff members, according to its LinkedIn profile. Since October 2019, Sarah Boyce has served as President and Chief Executive Officer, bringing over 25 years of experience in pharmaceutical and biopharmaceutical leadership. The senior management team includes:

• Steve Hughes, M.D., Chief Medical Officer, with over 20 years in clinical development and medical affairs
• W. Michael Flanagan, Ph.D., Chief Scientific Officer, who has led multiple therapeutic modality programs
• Michael MacLean, Chief Financial Officer, with over 30 years in strategic financial leadership

RNA therapeutics by Annie Spratt

Recent Developments

• On October 26, 2025, Novartis announced an agreement to acquire Avidity for USD 12 billion. Shareholders will receive USD 72.00 per share in cash upon closing, which is expected in the first half of 2026, following the spin-off of early-stage precision cardiology programs into a newly formed public company (SpinCo).
• On September 15, 2025, Avidity closed an underwritten public offering of 17,250,000 shares at USD 40.00 each, resulting in gross proceeds of USD 690 million to support the advancement of clinical programs and the establishment of commercial infrastructure.
• On October 27, 2025, Avidity’s share price increased by 43.34% to USD 70.45, with a trading volume of 4,760,707 shares.

Financial and Strategic Analysis

As of October 27, 2025, Avidity reported a market capitalization of approximately USD 7.17 billion (intraday) and a beta of 0.97 over five years. Key financial figures (trailing twelve months) include:

• Revenue: USD 10.73 million
• Net loss: USD 455.74 million
• Total cash: USD 1.18 billion
• Total debt to equity: 0.43%
• Price/Sales ratio: 526.10
• Price/Book ratio: 5.40

Strategically, Avidity’s AOC platform currently supports three clinical programs: myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. The platform’s ability to deliver RNA therapeutics to previously inaccessible tissues is significant for collaborations in cardiology and immunology. The merger with Novartis aims to utilize additional resources for late-stage development in neuroscience, while the spin-off is intended to facilitate focused advancement of precision cardiology candidates.

Market Position and Industry Context

In the biotechnology sector, Avidity operates at the intersection of antibody and oligonucleotide technologies, addressing rare and genetic diseases. Its muscle-directed delivery approach distinguishes it from traditional RNA modalities. Avidity’s beta, close to 1.0, indicates equity volatility in alignment with the broader market. Industry benchmarks, such as a one-year target estimate of USD 68.81 per share (Yahoo Finance), reflect market expectations for growth driven by clinical milestones, strategic transactions, and expanding partnerships.

tl;dr

On October 26, 2025, Avidity Biosciences agreed to be acquired by Novartis for USD 12 billion and will spin off its early-stage precision cardiology assets into a separate public entity prior to closing in the first half of 2026. The company raised USD 690 million in a September 2025 public offering and experienced a share price increase to USD 70.45 on October 27, 2025. Investors will observe the completion of the merger, SpinCo’s market debut, and progress in Avidity’s three clinical neuromuscular programs.